




LIFEFEST 2026

Nashville



SA53: A New Approach to p53-Driven Cancers

A Patient & Advocate Update


Dr. Greg Palmer



SA53: A New Approach to p53-Driven Cancers

A Patient & Advocate Update · Life Fest 2026, Nashville, TN

Understanding p53 & SA53




Watch: p53 & SA53 Explained

~2.5minutes

<https://youtu.be/rMCyuUnyWdg>



The Science, Made Simple



Why SA53 Is Different

- **Reaching higher doses safely.** SA53 has been approved to escalate to 16× its starting dose.
- **A clean safety profile so far.** Zero dose-limiting toxicities across all cohorts to date, with only mild (Grade 1) side effects observed at dose levels where earlier MDM2 drugs caused serious toxicity.
- **SA53 is an oral medication** — no infusion required.
- **Backed by strong preclinical data.** SA53 was optimized for efficacy and safety across more than 100 preclinical studies before ever reaching patients.




About Lamassu

- **Rooted in academic medicine.** Founded by physician-scientists from Duke University and Cleveland Clinic, with decades of experience in oncology research and translational science.
- **Patient-centered by design.** Every program decision is guided by one question: how does this help the patient in front of us, today?
- **Focused on unmet needs.** We concentrate on rare and underserved cancers — where the science is strong, options are few, and progress can change lives.
- **Committed for the long run.** We are building SA53 as a durable, patient-first therapy, not a short-term project.



Preclinical Data

Best-in-class *in vivo* Efficacy



CD-1 nude female n = 8

SJSA-1 (osteosarcoma) xenografts in CD-1 nude mice (p.o. administration in a q1dx14 schedule) dose 12,5 or 25 mg/kg.

Note: AD-O-21-22 is a backup compound from Lamassu



Clinical Plan

Phase I/IIa First-in-Human (NCT06578624)

A study of SA53-OS in adult participants
with locally advanced or metastatic solid tumors


Primary Endpoints:
Safety and tolerability
MTD and RP2D

Secondary Endpoints:
PK profile
Preliminary efficacy

Drinkable oral solution.

21 days cycle:

Single daily dose for 3 days + 18 days off



Clinical Trial: Now Enrolling

LB-SA53-101 · Phase 1/2a · NCT06578624

Who may be eligible (high level)

- Adults with an advanced or metastatic solid tumor
- Tumor confirmed to be p53 “wild-type” (normal, non-mutated)
- Standard treatments haven't worked, or aren't available
- Good overall organ function and performance status

Sites currently recruiting

- Cleveland Clinic — Cleveland, OH
- Gabrail Cancer Center — Canton, OH

Coming soon

- MD Anderson Cancer Center — Houston, TX
- University Hospitals / Case Comprehensive Cancer Center — Cleveland, OH
- Memorial Sloan Kettering – New York



Learn more or ask your care team about the trial



Standing With the Liposarcoma Community

- **We applaud Life Raft's advocacy.** The Life Raft Group and the Liposarcoma Support Network have given voice to patients and families asking for more options — including the Brigimadlin petition.
- **We welcome greater transparency.** Boehringer Ingelheim has published full Brightline-1 results in a peer-reviewed journal and committed to sharing patient-level data via Vivli.org — open data helps the whole field move faster, for every program, including ours.
- **Liposarcoma is a priority for us.** SA53's Phase 2a program includes a dedicated cohort for MDM2-amplified, p53 wild-type liposarcoma.
- **Rare cancers deserve real investment.** We're honored to stand alongside this community — we're in this together.





Lamassu

ACCELERATING HOPE AND HEALING

Contact

GregPalmer, PhD

greg.palmer@lamassubio.com



www.LamassuBioTech.com

LIFEFEST2026

Nashville



LIPOSARCOMA
SUPPORT  NETWORK

Thank you to our sponsors for supporting our mission to present high-quality education, engagement & support to the liposarcoma community!



IOVANCE
BIOTHERAPEUTICS



~~Cancer~~
UT MD Anderson

